$MRNA · Moderna, Inc.
Moderna entered Amendment No. 1 to its Credit and Guaranty Agreement with Ares Capital Corporation, effective November 9, 2026. The amendment reduces interest rate margins by 0.75 percentage points: SOFR-based loans from 5.50% to 4.75%, and base-rate loans from 4.50% to 3.75%. It also extends maturity from November 24, 2030 to November 24, 2031, and extends delayed draw availability periods for $400M and $500M of commitments to November 24, 2029.
- SOFR-based term loan margin cut from 5.50% to 4.75% per annum.
- Base-rate loan margin cut from 4.50% to 3.75% per annum.
- Maturity extended from November 24, 2030 to November 24, 2031.
- $400M delayed draw availability extended from November 24, 2027 to November 24, 2029.
- $500M delayed draw availability extended from November 24, 2028 to November 24, 2029.
Extended-hours last trade $213.21, down 0.96% vs regular close; the amendment is a routine financing tweak unlikely to drive the move.
Moderna locked in cheaper, longer-dated debt terms with Ares, reflecting improved credit standing and extending liquidity runway.
_Not applicable._
Borrowings of delayed draw term loans remain subject to applicable conditions under the Credit Agreement.